Screening for Abnormal Uterine Artery Remodeling

Abstract

Abnormal uterine artery remodeling is a pivotal pathophysiological event associated with adverse pregnancy outcomes, including preeclampsia and fetal growth restriction. Early identification through screening can potentially improve maternal-fetal outcomes by facilitating targeted surveillance and timely interventions. This article reviews current evidence on the mechanisms, risk factors, clinical implications, diagnostic modalities, management strategies, recent advances, and guideline-based recommendations for screening abnormal uterine artery remodeling, with an emphasis on integrating emerging scientific insights into clinical practice for obstetricians and maternal-fetal medicine specialists.

Introduction

Proper remodeling of the uterine arteries is fundamental for optimal placental perfusion and fetal development. Inadequate or abnormal remodeling has been recognized as a key factor underlying hypertensive disorders of pregnancy and intrauterine growth restriction. As research uncovers the molecular underpinnings and clinical predictors of abnormal uterine artery adaptation, the focus has shifted toward early screening and risk stratification among pregnant women. This review synthesizes the latest scientific findings, highlighting the practical significance and challenges of screening strategies in contemporary obstetric care.

Epidemiology / Disease Burden

Abnormal uterine artery remodeling affects approximately 5–10% of pregnancies, correlating with the global prevalence of preeclampsia and fetal growth restriction. The burden is particularly pronounced in low-resource settings, where access to screening and preventive care is limited, leading to increased maternal and neonatal morbidity and mortality. Epidemiological studies underscore the heterogeneity in prevalence, influenced by population risk profiles, maternal comorbidities, and health system factors. The far-reaching consequences include preterm birth, perinatal death, and long-term cardiovascular sequelae for both mother and child.

Pathophysiology

Normal uterine artery remodeling involves the transformation of spiral arteries into high-capacitance, low-resistance vessels, orchestrated by extravillous trophoblast invasion and modulation of the maternal immune environment. Impaired or incomplete remodeling results in persistent high-resistance flow, increased shear stress, and placental ischemia. This cascade triggers the release of antiangiogenic and inflammatory mediators, precipitating maternal endothelial dysfunction. The molecular basis includes dysregulation of angiogenic factors, such as VEGF and PlGF, and upregulation of sFlt-1 and endoglin, which are being explored as biomarkers for early detection and risk stratification.

Risk Factors

Several maternal and pregnancy-related factors are associated with abnormal uterine artery remodeling. These include advanced maternal age, pre-existing hypertension, diabetes, obesity, autoimmune disease, and a history of preeclampsia or growth restriction. Multiple gestations and assisted reproductive technologies also increase risk. Genetic predispositions, such as thrombophilic mutations and variations in angiogenic pathway genes, further modulate susceptibility. Identifying high-risk women is essential for targeted screening and prevention.

Clinical Features

Clinically, abnormal uterine artery remodeling is often asymptomatic in early pregnancy. However, it manifests later as signs and symptoms of preeclampsia hypertension, proteinuria, and end-organ dysfunction or as fetal growth restriction detected on ultrasonography. In some cases, abnormal Doppler findings may precede clinical manifestations, providing a window for early intervention. Severe cases may present with uteroplacental insufficiency, oligohydramnios, or abnormal fetal heart rate tracings, necessitating heightened surveillance and possible preterm delivery.

Diagnosis

Diagnosis primarily relies on Doppler ultrasonography of the uterine arteries, typically performed between 11 and 14 weeks gestation. Key parameters include the pulsatility index (PI), resistance index (RI), and the presence of early diastolic notching. Elevated PI (>95th percentile for gestational age) and bilateral notching are highly predictive of impaired remodeling and increased risk of adverse outcomes. Recent advances incorporate biochemical markers, such as PlGF, sFlt-1, and uterine artery-derived microRNAs, into multiparametric screening algorithms. Emerging evidence supports the integration of maternal clinical factors, Doppler indices, and serum biomarkers for improved predictive accuracy.

Treatment & Management

There is no definitive cure for abnormal uterine artery remodeling, but management focuses on risk mitigation and surveillance. Low-dose aspirin initiated before 16 weeks gestation is recommended for high-risk women to reduce the incidence and severity of preeclampsia. Antenatal surveillance includes serial growth scans, Doppler assessments, and evaluation of maternal symptoms. In severe cases, hospitalization, corticosteroids for fetal lung maturity, and timely delivery are indicated. Multidisciplinary care involving obstetricians, maternal-fetal medicine specialists, and anesthesiologists is essential for optimizing outcomes.

Recent Advances / Emerging Therapies

Recent research has refined risk prediction models through the combination of uterine artery Doppler, maternal characteristics, and novel biomarkers. Advances in imaging including three-dimensional power Doppler and placental perfusion MRI offer improved sensitivity for detecting abnormal vascular remodeling. Experimental therapies targeting angiogenic imbalance and immunomodulation are under investigation, though none are yet standard of care. Artificial intelligence-driven algorithms hold promise for individualized risk assessment and early intervention strategies.

Guideline Recommendations

Major guidelines, including those from the International Society for the Study of Hypertension in Pregnancy (ISSHP) and the American College of Obstetricians and Gynecologists (ACOG), advocate first-trimester uterine artery Doppler screening in women at increased risk for preeclampsia and related complications. Aspirin prophylaxis is recommended for women with abnormal findings or multiple risk factors. Guidelines emphasize shared decision-making, patient education, and the integration of screening results with clinical judgment to guide management.

Conclusion

Screening for abnormal uterine artery remodeling represents a cornerstone in the prevention of hypertensive disorders of pregnancy and fetal growth restriction. Advances in diagnostic modalities and biomarker discovery have enhanced early detection and risk stratification, enabling timely prophylactic interventions. Continued research and guideline development are essential to further refine screening protocols, improve accessibility, and ultimately reduce the global burden of maternal and perinatal morbidity and mortality associated with abnormal uterine vascular adaptation.